Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2025-05-02 00:00:00 ET · period of report 2025-05-01 · accession 0001415889-25-011773 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-02 | 2025-05-01 | HALO | Krishnan Mahesh | Dir | A - Grant | $0.00 | +4,165 | 10.7K | +64% | $0 |
| D | 2025-05-02 | 2025-05-01 | HALO | Krishnan Mahesh | Dir | A - Grant | $0.00 | +5,750 | 5,750 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-01 | A | A | 4,165 | $0.00 | 10,666 | D | — | — | (F1) Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. |
| 2 | Derivative | Option to Purchase Common Stock | 2025-05-01 | A | A | 5,750 | $0.00 | 5,750 | D | $60.03 · — to 2035-05-01 | 5,750 Common Stock | (F2) Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. |